[1] 中国临床肿瘤学会(CSCO)甲状腺癌专家委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医师协会外科医师分会甲状腺外科医师委员会, 等.  碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019, 29(6): 476-480.   doi: 10.19401/j.cnki.1007-3639.2019.06.013
Chinese Society of Clinical Oncology (CSCO) Thyroid Cancer Expert Committee, Chinese Research Hospital Association Thyroid Disease Committee, Chinese Thyroid Association, Chinese Collage of Surgeons, Chinese Medical Doctor Association, et al.  Consensus on the diagnosis and management of iodine-refractory differentiated thyroid cancer (2019 edition)[J]. China Oncol, 2019, 29(6): 476-480.   doi: 10.19401/j.cnki.1007-3639.2019.06.013
[2] Shangguan LJ, Fang SW, Zhang PP, et al.  Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy[J]. Ann Nucl Med, 2019, 33(3): 177-183.   doi: 10.1007/s12149-018-01321-w
[3] 李慧.  核医学分子影像在分化型甲状腺癌中的应用现状与进展[J]. 中国癌症杂志, 2018, 28(7): 481-486.   doi: 10.19401/j.cnki.1007-3639.2018.07.001
Li H.  Molecular imaging of nuclear medicine in differentiated thyroid cancer: current status and future direction[J]. China Oncol, 2018, 28(7): 481-486.   doi: 10.19401/j.cnki.1007-3639.2018.07.001
[4] Manohar PM, Beesley LJ, Bellile EL, et al.  Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer[J]. Clin Nucl Med, 2018, 43(9): 641-647.   doi: 10.1097/RLU.0000000000002193
[5] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会.  分化型甲状腺癌术后管理中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(9): 1021-1028.   doi: 10.19538/j.cjps.issn1005-2208.2020.09.04
Chinese Thyroid Association, Chinese Collage of Surgeons, Chinese Medical Doctor Association, Chinese Research Hospital Association Thyroid Disease Committee.  Expert consensus on postoperative management of differentiated thyroid cancer (2020 edition)[J]. Chin J Pract Surg, 2020, 40(9): 1021-1028.   doi: 10.19538/j.cjps.issn1005-2208.2020.09.04
[6] Larg MI, Barbus E, Gabora K, et al.  18F-FDG PET/CT in differentiated thyroid carcinoma[J]. Acta Endocrinol (Buchar), 2019, 15(2): 203-208.   doi: 10.4183/aeb.2019.203
[7] Leboulleux S, Schroeder PR, Busaidy NL, et al.  Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2009, 94(4): 1310-1316.   doi: 10.1210/jc.2008-1747
[8] Leenhardt L, Leboulleux S, Bournaud C, et al.  Recombinant thyrotropin vs levothyroxine withdrawal in 131I therapy of N1 thyroid cancer: a large matched cohort study (ThyrNod)[J]. J Clin Endocrinol Metab, 2019, 104(4): 1020-1028.   doi: 10.1210/jc.2018-01589
[9] Whiting PF, Rutjes AWS, Westwood ME, et al.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8): 529-536.   doi: 10.7326/0003-4819-155-8-201110180-00009
[10] Esteva D, Muros MA, Llamas-Elvira JM, et al.  Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer[J]. Ann Surg Oncol, 2009, 16(7): 2006-2013.   doi: 10.1245/s10434-009-0483-8
[11] Giovanella L, Ceriani L, De Palma D, et al.  Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas[J]. Head Neck, 2012, 34(5): 626-631.   doi: 10.1002/hed.21791
[12] Vural GU, Akkas BE, Ercakmak N, et al.  Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data[J]. Clin Nucl Med, 2012, 37(10): 953-959.   doi: 10.1097/RLU.0b013e31825b2057
[13] Kunawudhi A, Pak-art R, Keelawat S, et al.  Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan[J]. Clin Nucl Med, 2012, 37(6): 561-567.   doi: 10.1097/RLU.0b013e318252d30e
[14] Ozkan E, Aras G, Kucuk NO.  Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results[J]. Clin Nucl Med, 2013, 38(5): 326-331.   doi: 10.1097/RLU.0b013e318286827b
[15] Giovanella L, Trimboli P, Verburg FA, et al.  Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma[J]. Eur J Nucl Med Mol Imaging, 2013, 40(6): 874-880.   doi: 10.1007/s00259-013-2370-6
[16] Kundu P, Lata S, Sharma P, et al.  Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT[J]. Eur J Nucl Med Mol Imaging, 2014, 41(7): 1354-1362.   doi: 10.1007/s00259-014-2723-9
[17] 胡斌, 王锦锋, 毛秋粉.  18F-FDGPET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J]. 国际放射医学核医学杂志, 2015, 39(3): 242-246, 251.   doi: 10.3760/cma.j.issn.1673-4114.2015.03.012
Hu B, Wang JF, Mao QF.  The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J]. Int J Radiat Med Nucl Med, 2015, 39(3): 242-246, 251.   doi: 10.3760/cma.j.issn.1673-4114.2015.03.012
[18] Ma C, Wang X, Shao M, et al.  18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans[J]. Q J Nucl Med Mol Imaging, 2015, 59(2): 220-227.
[19] Elboga U, Karaoglan H, Sahin E, et al.  F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience[J]. Eur Rev Med Pharmacol Sci, 2015, 19(3): 396-401.
[20] Choi SJ, Jung KP, Lee SS, et al.  Clinical usefulness of F-18 FDG PET/CT in Papillary thyroid cancer with negative radioiodine scan and elevated thyroglobulin level or positive anti-thyroglobulin antibody[J]. Nucl Med Mol Imaging, 2016, 50(2): 130-136.   doi: 10.1007/s13139-015-0378-5
[21] 薛明媚, 刘保平, 谢新立, 等.  18F-FDG PET/CT检测Tg阳性而131I-诊断剂量全身显像阴性分化型甲状腺癌患者复发和转移[J]. 中国医学影像技术, 2016, 32(2): 218-222.   doi: 10.13929/j.1003-3289.2016.02.014
Xue MM, Li BP, Xie XL, et al.  18F-FDG PET/CT in detection of recurrence or metastatic of DTC patients with elevated serum Tg levels and negative 131I-Dx-WBS[J]. Chin J Med Imaging Technol, 2016, 32(2): 218-222.   doi: 10.13929/j.1003-3289.2016.02.014
[22] 程旭, 李永军, 许昕丹, 等.  18F-FDG PET/CT检测131I-治疗剂量全身显像阴性而甲状腺球蛋白阳性分化型甲状腺癌复发和转移[J]. 中国医学影像技术, 2018, 34(6): 855-859.   doi: 10.13929/j.1003-3289.201711001
Cheng X, Li YJ, Xu XD, et al.  18F-FDG PET/CT in detection of recurrence and/or metastasis of differentiated thyroid carcinoma in patients with elevated serum thyroglobulin levels and negative 131I post-therapy whole body scan[J]. Chin J Med Imaging Technol, 2018, 34(6): 855-859.   doi: 10.13929/j.1003-3289.201711001
[23] Piccardo A, Trimboli P, Puntoni M, et al.  Role of 18F-choline positron emission tomography/computed tomography to detect structural relapse in high-risk differentiated thyroid cancer patients[J]. Thyroid, 2019, 29(4): 549-556.   doi: 10.1089/thy.2018.0552
[24] Albano D, Tulchinsky M, Dondi F, et al.  Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma[J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 461-468.   doi: 10.1007/s00259-020-04992-8
[25]

Almeida LS, Araújo ML, Santos AO, et al. Head-to-head comparison of F-18 FDG PET/CT in radioidine refractory thyroid cancer patients with elevated versus suppressed TSH levels a pilot study[J/OL]. Heliyon, 2020, 6(3): e03450[2021-03-16]. https://www.sciencedirect.com/science/article/pii/S2405844020302954. DOI: 10.1016/j.heliyon.2020.e03450.
[26]

Giovanella L, Deandreis D, Vrachimis A, et al. Molecular imaging and theragnostics of thyroid cancers[J/OL]. Cancers (Basel), 2022, 14(5): 1272[2022-04-01]. https://www.mdpi.com/2072-6694/14/5/1272. DOI: 10.3390/cancers14051272.
[27]

Zampella E, Klain M, Pace L, et al. PET/CT in the management of differentiated thyroid cancer[J/OL]. Diagn Interv Imaging, 2021, 102(9): 515−523[2022-04-01]. https://www.sciencedirect.com/science/article/abs/pii/S2211568421000851?via%3Dihub. DOI: 10.1016/j.diii.2021.04.004.
[28]

Lodi Rizzini E, Repaci A, Tabacchi E, et al. Impact of 18F-FDG PET/CT on clinical management of suspected radio-iodine refractory differentiated thyroid cancer (RAI-R-DTC)[J/OL]. Diagnostics (Basel), 2021, 11(8): 1430[2022-04-01]. https://www.mdpi.com/2075-4418/11/8/1430. DOI: 10.3390/diagnostics11081430.
[29]

Ferrari C, Santo G, Ruta R, et al. Early predictive response to multi-tyrosine kinase inhibitors in advanced refractory radioactive-iodine differentiated thyroid cancer: a new challenge for [18F]FDG PET/CT[J/OL]. Diagnostics (Basel), 2021, 11(8): 1417[2022-04-01]. https://www.mdpi.com/2075-4418/11/8/1417. DOI: 10.3390/diagnostics11081417.
[30] Leger FA, Izembart M, Dagousset F, et al.  Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma[J]. Eur J Nucl Med, 1998, 25(3): 242-246.   doi: 10.1007/s002590050223
[31] 邹仁健, 傅宏亮, 吴靖川, 等.  分化型甲状腺癌131I治疗中多种核素显像的联合应用[J]. 上海交通大学学报(医学版), 2010, 30(3): 256-258.   doi: 10.3969/j.issn.1674-8115.2010.03.003
Zou RJ, Fu HL, Wu JC, et al.  Clinical value of combination of multiple radionuclide imaging methods in 131I therapy for differentiated thyroid carcinoma[J]. J Shanghai Jiaotong Univ: Med Sci, 2010, 30(3): 256-258.   doi: 10.3969/j.issn.1674-8115.2010.03.003
[32] Ma C, Xie JW, Lou YH, et al.  The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis[J]. Eur J Endocrinol, 2010, 163(2): 177-183.   doi: 10.1530/EJE-10-0256